 
 Randomized Control led Trial to Evaluate an 
Implementation Strategy to Increase Optimal Use of 
HPV Vaccine in Primary Care  
 
National Clinical Trial (NCT) Identified Number:  
 
Principal Investigator: Jason Newland  
 
Sponsor:  Washington University School of Medicine  
 
Grant Title: Randomized Control led Trial to Evaluate an Implementation 
Strategy to Increase Optimal Use of HPV Vaccine in Primary Care  
 
Grant Number: R01CA2356515- 01A1  
 
Funded by: National Institute of Health  
 
Version Number: 1. 10 
 
6 February , 2022 
 
 
 
Summary of Changes from Previous Version:  
Affected Section(s)  
 
1.3 and 6.3               Summary of Revisions Made  
           Updated the fidelity score template.   
                        Rationale  
 The fidelity score template was  
updated to prevent any subjective bias.  
The scoring timeline was updated from  
every 6 months to annually.   
 
 
  
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
1 
  
  
 
 Table of Contents   
 
Statement of Compliance  ....................................................................................................................................... 3 
Investigator's Signature  ....................................................................................................................................... 3 
1 Protocol Summary ............................................................................................................................................... 4 
1.1 Synopsis  ....................................................................................................................................................... 4 
1.2 Schema  ......................................................................................................................................................... 6 
1.3 Schedule of Activities  ................................................................................................................................... 6 
2    Introduction ...................................................................................................................................................... 8 
2.1 Study Rationale  ............................................................................................................................................ 8 
2.2 Background .................................................................................................................................................. 8 
2.3 Risk/Benefit Assessment  ............................................................................................................................. 12 
2.3.1 Known Potential Risks  ......................................................................................................................... 12 
2.3.2 Known Potential Benefits  ..................................................................................................................... 12 
2.3.3 Assessment of Potential Risks and Benefits  .......................................................................................... 13 
3 Objectives and Endpoints ................................................................................................................................... 14 
4 Study Design ..................................................................................................................................................... 16 
4.1 Overall Design  ............................................................................................................................................ 16 
4.2 Scientific Rationale for Study Design  .......................................................................................................... 16 
4.3 Justification for Intervention  ....................................................................................................................... 17 
4.4 End-of-Study Definition  .............................................................................................................................. 17 
5 Study Population ............................................................................................................................................... 18 
5.1 Inclusion Criteria  ........................................................................................................................................ 18 
5.2 Exclusion Criteria  ....................................................................................................................................... 18 
5.3 Lifestyle Considerations  .............................................................................................................................. 18 
5.4 Screen Failures  ........................................................................................................................................... 19 
5.5 Strategies for Recruitment and Retention  ..................................................................................................... 19 
6 Study Intervention(s) or Experimental Manipulation(s)  ...................................................................................... 21 
6.1 Study Intervention(s) or Experimental Manipulation(s) Administration ........................................................ 21 
6.1.1 Study Intervention or Experimental Manipulation Description .............................................................. 21 
6.1.2 Administration and/or Dosing ............................................................................................................... 21 
6.2 Fidelity  ....................................................................................................................................................... 23 
6.2.1 INTERVENTIONIST TRAINING AND TRACKING .......................................................................... 23 
6.3 Measures to Minimize Bias: Randomization and Blinding  ........................................................................... 27 
6.4 Study Intervention/Experimental Manipulation Adherence  .......................................................................... 27 
7 Study Intervention/Experimental Manipulation Discontinuation and Participant Disc ontinuation/Withdrawal  ..... 30 
7.1 Discontinuation of Study Intervention/Experimental Manipulation  .............................................................. 30 
7.2 Participant Discontinuation/Withdrawal from the Study  ............................................................................... 30 
7.3 Lost to Follow -Up....................................................................................................................................... 30 
8 Study Assessments and Procedures  ................................................................................................................... 31 
8.1 Endpoint and Other Non -Safety Assessments .............................................................................................. 31 
8.3 Adverse Events and Serious Adverse Events  ............................................................................................... 32 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
2 
 8.3.1 Definition of Adverse Events  ................................................................................................................ 32 
8.4 Una nticipated Problems  .............................................................................................................................. 32 
8.4.1 Definition of Unanticipated Problems  ................................................................................................... 32 
8.4.2 Unanticipated Problems Reporting  ........................................................................................................ 32 
9 Statistical Considerations  ................................................................................................................................... 33 
9.1 Statistical Hypotheses  .................................................................................................................................  33 
9.2 Sample Size Determinations  ........................................................................................................................ 33 
9.3 Populations for Analyses  ............................................................................................................................. 33 
9.4 Statistical Analyses  ..................................................................................................................................... 33 
9.4.1 General Approach ................................................................................................................................ 33 
9.4.2 Analysis of the Primary Endpoint(s)  ..................................................................................................... 34 
9.4.3 Analysis of the Secondary Endpoint(s) .................................................................................................. 35 
9.4.4 Safety Analyses  .................................................................................................................................... 36 
9.4.5 Baseline Descriptive Statistics  ............................................................................................................ 367 
9.4.6 Planned Interim Analyses  ..................................................................................................................... 36 
9.4.7 Sub -Group Analyses ............................................................................................................................. 36 
9.4.8 Tabulation of Individual Participant Data  .............................................................................................. 37 
9.4.9 Exploratory Analyses  ........................................................................................................................... 38 
10 Supporting Documentation and Operational Considerations .............................................................................. 38 
10.1 Regulatory, Ethical, and Study Oversight Considerations  ........................................................................... 38 
10.1.2 Study Discontinuation and Closure  ..................................................................................................... 38 
10.1.6 Safety Oversight  .................................................................................................................................  39 
10.3 Abbreviations and Special Terms  .............................................................................................................. 40 
10.4 Protocol Amendment History  .......................................................................................................................  41 
11 References  ................................................................................................................................................... 43 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
3 
 STATEMENT OF COMPLIA NCE  
1. The trial will be carried out in accordance with International Council on Harmonisation Good 
Clinical Practice (ICH GCP) and the following:  
o United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 
CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812).  
National Institutes of Health (NIH) -funded investigators and clinical trial site staff who are 
responsible for the conduct, management, or oversight of NIH -funded clinical trials have 
completed Human Subjects Protection and ICH GCP Training.  
 
The protocol,  informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the IRB for review and approval. Approval of both the protocol and the consent 
form(s) must be obtained before any participant is consented. Any amendment to the protocol 
will require review and approval by the IRB before the changes are implemented to the study. 
All changes to the consent form(s) will be IRB approved; a determination will be made regarding 
whether a new consent needs to be obtained from par ticipants who provided consent, using a 
previously approved consent form.  
 
INVESTIGATOR'S SIGNAT URE  
Principal Investigator or Clinical Site Investigator:  
Signed:  
  Date:  
8/26/2022    
Name*:   Jason Newland  
Title*:   Professor of Pediatrics  
Pediatric Infectious Diseases  
Vice Chair of Community Health and Strategic Planning  
 
Investigator Contact Information:  
Affiliation*:   Washington University   
Address:   660 South Euclid Saint Louis, MO 63110  
Telephone:   314-454-8613  
Email:            jgnewland@wustl.edu  
 

HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
4 
 1 PROTOCOL SUMMARY  
1.1 SYNO PSIS  
Title:  Randomized Contro lled Trial to Evaluate an Implementation Strategy to Increase 
Optimal Use of HPV Vaccine in Primary Care  
Grant Number:  R01CA2356515 -01A1  
Study Description:  We will complete a cluster -randomized trial to evalu ate the effectiveness of a 
multi -component implementation strategy (the intervention) to increase use of 
the HPV vaccine according to CDC guidelines. Twenty community pediatric 
practices will be randomly assigned to the intervention or wait -list control 
condition.  
Objectives*:  Primary Objective:  Compare , at 24 months,  the proportion of eligible 
preteens who receive 1st dose (primary endpoint ) and 
2nd dose (secondary endpoint ) of HPV vaccine before 
their 13th birthday in practices that receive the 
intervent ion with practices in the wait -list control 
group.   
Secondary Objectives:  Compare these outcomes at 36 months to assess the 
sustainability of intervention benefit.  
 
Determine whether the intervention effect on 
vaccination outcomes is mediated by providers ’ 
increased belief in their capabilities to provide on -time 
HPV vaccination (primary outcome) and by their increased use of a presumptive, announcement 
approach to recommend HPV vaccine (secondary 
outcome)  
 
Explore if the intervention effect on vaccinatio n 
outcomes is mediated by the degree of practice change 
as measured on an 18 -item HPV vaccine delivery score.  
 
Assess the implementation fidelity, the acceptability 
and appropriateness of the intervention for providers, parental satisfaction with care, an d cost.  
 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
5 
 Endpoints*:  Primary Endpoint:  The proportion of eligible preteens who receive the 1st 
dose of HPV vaccine before their 13th birthday at 24 
months  post randomization .  
 The proportion of eligible preteens who receive the 
2nd dose of HPV vaccine before their 13th birthday at 24 months  post randomization . 
Secondary Endpoint:  The proportion of eligible preteens who receive the 1st 
dose of HPV vaccine before their 13th birt hday at 36 
months  post randomization.  
 
The proportion of eligible preteens who receive the 
2nd dose of HPV vaccine before their 13th birthday at 
36 months  post randomization .  
 
 
Study Population:  Approximately 120 Community based pediatric prim ary care providers  in the St. 
Louis metropolitan area , who work in the 20 participating practices  
Phase* or Stage:  3 (Low -risk behavioral intervention)  
 
Description of Sites/Facilities 
Enrolling Participants:      The study will be conducted at Washingt on University   
Description of Study 
Intervention/Experimental 
Manipulation:  The theory -based, multi -component intervention includes: 1) an educational 
video; 2) audit and feedba ck of vaccine coverage; 3) a communication 
strategy to improve discussion of HPV vaccine ; and 4) practice facilitation to 
support practice change. The intervention will be delivered through a series of brief practice visits with the facilitator that occur every 1 -4 weeks over 2 
years.  All providers (intervention and control groups) will receive information 
provided by the CDC to assist motivated providers who want to improve use of HPV vaccine tha t are representative of “usual care.” These will include the 
current recommendations, background information and the CDC’s patient educational materials and website.  All providers will also receive Baseline HPV 
vaccination rates.   
 
Study Duration*:   5 years  
Participant Duration:  3-5 years  
 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
6 
 1.2 SCHEMA  
 
 
1.3 SCHEDULE OF ACTI VITIES  
Time  Participant  Study activities  
Baseline  Provider  Complete provider survey  
   
 Practice  Complete  review of EMR data  
 Practice  Complete  practice survey and assess HPV vaccine 
delivery  
   
12-months  Provider  Complete provider survey  
 Practice  Complete  review of EMR data  
 Practice  Assess  HPV vaccine delivery  
 Intervention Practice  Assess intervention fidelity  
   

HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
7 
 24-months  Provider  Complete provider survey  
   
 Practice  Complete review of EMR data  
 Practice  Assess  HPV vaccine delivery  
 Intervention Practice  
Intervention Practice  Assess intervention fidelity  
Complete an exit interview  
36-month  Practice  Complete  review of EMR data  
 
      
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
8 
 2    INTRODUCTION  
2.1 STUDY RATIONALE  
The vaccine targeting oncogenic strains of the huma n papilloma virus (HPV) can prevent commonly 
occurring cancers if given to girls and boys before sexual debut. Yet, in the United States (U.S.), more 
than 10 years after introduction of the vaccine, fewer than half of the target population are vaccinated,
1,2 a far cry from the Healthy People 2020 goal of 80% coverage.3 Even though vaccination 
coverage has been increasing among 13 -17 year old females, 40% report receiving the vaccine after 
sexual debut, when vaccination benefit is less certain.1 It is estima ted that for every year of low vaccine 
coverage in the US, 4,400 girls will have a future cervical cancer.4 Innovative strategies are urgently 
needed to increase optimal use of this effective, safe vaccine.  
National recommendations from the Centers for Dis ease Control and Prevention (CDC) are to complete 
the 2 -dose HPV vaccine series by age 13.5 Uptake of the tetanus -diphtheria -pertussis booster (Tdap) and 
the meningococcal vaccine (MCV), two other vaccines required by age 13 for school attendance, are 
over  80% across the country.2 Yet, vaccination of HPV vaccine remains low (~39% in 2017), with little 
year- to-year improvement in this age -group.1,2 To date, efforts to increase vaccine use have, at best, 
increased vaccine initiation by 10% with no impact on v accine completion by age 13 and no evidence of 
sustained benefit.  
Our objective is to evaluate the effectiveness of a promising, innovative intervention to make significant 
improvements in optimal HPV vaccine use. The multi -component intervention is based on the 
Theoretical Domains Framework (TDF) theory of behavior- change and uses practice facilitation to 
support practice change. It includes strategies to increase provider communication skills and their belief in their capabilities to deliver HPV vaccine b y age 13 and supports implementation of a comprehensive 
system for HPV vaccine delivery. Preliminary results from pilot testing in 6 practices show a 19 -
percentage point increase in HPV vaccine initiation in the 15 -months from pre - to post -intervention 
(62% to 81%), reaching the target for Healthy People 2020.
3 A rigorous evaluation is needed to establish 
the effectiveness of the intervention in a generalizable sample prior to scaling for widespread use. In this study, the study population will comprise 20 primary care pediatric practices in the St. Louis metropolitan area , where only 40% of 13-  17 year -olds have completed the HPV vaccine series.
2 Vaccine 
use will be assessed at baseline, at 24 months to assess effectiveness of the intervention,  and at 36 
months to assess if change is sustained. We will investigate the mechanism of action of the intervention 
and assess features of the intervention that are important for scaling, including cost . 
 
2.2 BACKGROUND  
The full benefit to HPV vaccine to prevent cervical cancer and other genitourinary cancers is not being 
realized. HPV is the most common sexually transmitted virus in the U.S. with a prevalence of 33% among 
14- to 19 -year olds.1 Several HPV strains are oncogenic causing 31,500 new urogenital and oral cancers 
in men and women each year.6 Most of these cancers could be prevented by vaccination with HPV 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
9 
 vaccine prior to sexual debut as recommended by the CDC.1,6 Yet, uptake of this c ancer -preventing 
vaccine has been slow and in 2017, only 49% of adolescents ages 13 to 17 had completed the HPV 
vaccine series (53% of females, 44% of males) .2 Self-reported data from the National Health and 
Nutrition Examination Survey (NHANES) suggest t hat although vaccination has significantly increased in 
the past 10 years among females in this age - group, 40% will not get the full benefit of the vaccine as 
they received the vaccine after initiating sexual activity.1 Coverage by age 13 (i.e., before th eir 13th 
birthday), the age targeted by the CDC recommendations and a HEDIS quality measure, is lower for both 
girls and boys, although data for this age -group are not routinely reported. In 2017, uptake of HPV 
vaccine in 13 -year- olds was 39% and previous studies have shown little year -to-year improvement in 11 -
12 year -olds.1,6 There is an obvious disparity in uptake when compared with Tdap (88%) and MCV4 
(82%), vaccines that are required by age 13 for school attendance.6,7 It is estimated that for every ye ar of 
low vaccine coverage, 4,400 girls will have a future cervical cancer.4 Also, the annual direct cost of 
preventing and treating vaccine -preventable HPV -related disease is estimated to be $8.0 billion.8 There 
is an urgent need for a large increase in t he optimal use of this effective, safe vaccine.  
  
To date, interventions to increase HPV vaccination have had limited success. Single -component 
interventions targeting parents and providers have had mixed results. Educational interventions 
targeting parent s’ belief that their child is not at risk for HPV infection have not been effective,9 and 
parental hesitancy continues to be a barrier to vaccine use.10,11 Provider -focused strategies such as 
reminder systems, audit and feedback, and educational outreach, while effective in increasing the use of 
other vaccines, have had inconsistent results for increasing HPV vaccination.12 -14 When used 
concurrently, HPV vaccination increased by 5 -10%,12,13,15 -18 and in one study, improvements were 
sustained for at least six months.19 Studies showing larger effects have been criticized for being 
methodologically deficient.9,12 Policy change approaches such as requiring HPV vaccine for school 
attendance that have been effective in other countries have not been effective in the U.S., possibly due to generous opt -out provisions.
12,14 A systematic review of the literature indicated that high quality HPV 
vaccine communication was vital for increasing coverage,20 yet few interventions have tried to improve 
provider communication skills. One study compared presumptive announcements, in which providers assume parent readiness to vaccinate, with conversational, explanatory approaches, and found presumptive announcements were more effective.
15 A recent randomized trial by Dempsey et a l. 
showed that a 5 -component communication intervention to support a presumptive recommendation 
for HPV increased initiation for 11 -17 year -olds by 9%, with most improvement occurring at well -child 
visits.21 Vaccine completion did not change in interventio n sites and decreased in control sites. 
Sustainability of the impact of this intervention on vaccination rates was not assessed.  
  
Primary care providers face considerable barriers when trying to implement the CDC recommendations 
for HPV vaccine.22, 23  Over 60% of office -based primary care physicians, including pediatricians, work in 
practices with 5 or fewer physicians. 24 These practices are largely small -scale, independently run 
enterprises, operate on a narrow margin and lack the infrastructure to suppo rt practice change. 25 -28 
Yet, a body of NIH -funded research suggests primary care practices are complex adaptive systems and 
interventions to effect sustained change in care delivery must themselves be sustained (~2years) and 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
10 
 
tailored to the unique value s, structures and processes for each practice. 28 -32 External motivators for 
improvement can be important.28, 33, 34 Our formative work suggests two important external motivators 
that could encourage increased optimal use of the HPV vaccine: the requireme nt for active participation 
in an approved quality improvement (QI) activity for The American B oard of Pediatrics (ABP) 
maintenance of certification (MOC); and financial incentives for “meaningful use of data” for practices 
designated as a patient -centered  medical home. However, even those who are motivated to address 
this gap in care likely need help to change their clinical practice.  
  
Practice facilitators support change in primary care practices by empowering and supporting providers 
and staff to engage  in the change process together. Using participatory methods, practice facilitators 
help demystify improvement methods and support data -driven decision -making, tailoring their 
approach to meet practice needs. External facilitation has been used successfull y in a wide range of 
primary care practice settings to increase preventive care for adults and children.29, 35- 41 Improvement in 
the desired clinical care activity varied by activity, but was consistently at least 10%. 36-38, 40, 41 Follow -up 
studies have demonstrated changes in care delivery were sustained for up to six years, suggesting they 
had become instutionalized.29, 35 We did not identify any studies where practice facilitation was used to 
increase vaccination, but in one proj ect to improve diabetes care, annual influenza vaccine increased by 
15%.32  
 
There is a critical need for theory -based implementation interventions to improve the use of HPV 
vaccine and sustain benefit. Improving use of evidence -based practices requires behavior change, and in 
order to design effective interventions and allow purpo seful improvements when interventions fail, it is 
necessary to understand these behaviors in context. Models and theories of behavior and behavior 
change can be used to determine who and what needs to change and to identify behavior change 
strategies. To this end, Damschroder and colleagues developed the Consolidated Framework for 
Implementation Research (CFIR) to consolidate and unify key constructs from 19 published 
implementation theories.42  The  CFIR  identifies  five major  domains  that influence  successf ul 
implementation: characteristics  of the intervention, the inner  setting  (the context through  which  
implementation  will proceed), the outer setting  (the context in  which  the organization resides),  
implementer’s  characteristics,  and the processes  of implementation.42 Michie  and colleagues  
consolidated  33 theories  of behavior  and behavior  change  in order  to develop  a theoretical  framework  
for understanding  behavior  change  among  health  professionals.  43-45 Using  consensus  among  experts, 
they  identified  a framework  with  14 theoretical  domains  covering  the main  factors influencing  provider’s  
clinical behaviors  and behavior  change  (Theoretical  Domain Framework,  TDF).  43, 45,46    We have  used  the 
CFIR  and TDF to inform development of  our intervention  as indicated  in Figure  1. 
 
 
 
 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
11 
 Guided by the CFIR ,42 we conducted semi -structured interviews with 16 providers from 10 practices to 
systematically identify barriers to HPV vaccination in pediatric practices 47 This in vestigation revealed 
that all providers were  aware of the CDC recommendations for HPV vaccination and universally assumed 
responsibility for vaccine delivery. Typically, for both girls and boys, providers recommended the HPV 
vaccine at the 11 -12-year- old c heck -up visit. All but one provider used an explanatory style for this 
discussion, and the strength of their recommendation varied. All reported that persuading hesitant 
parents to vaccinate was difficult and time consuming; some delayed these discussions until the child 
was older and the parents were more accepting. Teamwork to deliver the vaccine series was uncommon, and no providers were aware of their partners’ approach to HPV vaccination or monitored 
vaccine coverage.  
Using 2014 data, we found that vac cine initiation and completion by age 13 varied among providers 
from 2% to 26%, and 1% to 26%, respectively, and varied 4 to 5- fold among providers within the same 
practice. These data demonstrate the urgent need for changes in vaccine delivery in communit y-based 
practices in our community to increase optimal use of this vaccine. By comparing factors between 
providers with higher and lower HPV vaccine coverage, we identified 
14 CFIR constructs across all five 
domains of the conceptual framework that were important barriers to following CDC guidelines.48 Most 
distinguishing factors related to provider characteristics –  their lack of buy -in to vaccination by age 13, 
their lack of confidence to address parental hesitancy, and poor communication skills to promote timely HPV vaccine use. Coverage was higher in practices with coordination between the provider and staff to 
ensure opportunities for vaccination were not missed. As describ ed in our recent publication,
 47 we 
crafted an implementation strategy (the intervention) to address these factors, guided by the TDF.43, 46 
The intervention was further developed during a practice quality improvement project,  described  below.  
  
For ~15- months, a practice facilitator has worked with 6 practices (20 providers) to implement the 
intervention, first targeting initiation of HPV vaccine by age 13. All practices were provided with their 
baseline data and received education about the potential bene fit for patients and the practice for 
following CDC recommendations, a communication strategy, and patient education materials. They 
identified a QI team and worked with the facilitator towards the practice’s goals for improvement. Each 
practice completed Plan -Do-Study -Act (PDSA) cycles, testing different strategies to improve care. PDSA 
cycles are small cycles of change that involve reviewing data to assess gaps in performance, identifying 
possible changes to improve care, selecting and testing an improvem ent strategy, and monitoring and 
adjusting new processes for care delivery. To date, the number of team meetings with the facilitator varied from 7 to 11, 10% were by phone, and each visit lasted < 1 hour.  
 
For each provider, HPV initiation was assessed on  a randomly selected sample of ~30 patients, 11.0 to 
13.0 years old with at least one practice visit (well- child or acute care visit) between June 1st and 
September 30th in the measurement period. These included 2016, 2017, and 2018. Overall, there was a 
19-percentage point increase in HPV vaccine initiation in the 15 - months from pre - to post -intervention 
(62% to 81%), reaching the target for Healthy People 2020.3 Results varied within and across practices as 
shown in Figure 2.  
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
12 
 
 
 
 
 
 
 
 
  
 
  
Efforts to impact vaccine compl etion by age 13 were initiated in March 2018, and after only 7 months, 
we observed a 12% increase. The majority (>80%) of providers felt the following features of the 
intervention were very important in the change process: access to the practice facilitato r, the QI practice 
team, help with measurement and review of vaccination data, and the communication strategy, and all 
would strongly recommend the program to their colleagues  
  
These findings suggest that the proposed 2 -year intervention is feasible and l ikely to have a large impact 
and sustained benefits.  
 
2.3 RISK/BENEFIT ASS ESSMENT  
2.3.1 KNOWN POTENTIA L RISKS  
 
There are no  immediate or long term  physical or p sychological risks associated with study participation. 
There are no study products. The intervention promotes national recommendations for use of HPV vaccine, a safe, effective vaccine for cancer prevention.  
 
There is a possibility that during routine cha rt audits , confidentiality could be compromised.   
  
2.3.2 KNOWN POTENTIA L BENEFITS  
 A long -term benefit to s ociety could be  the identification of an effective intervention to increase optimal 
use of the canc er preventing HPV vaccine. Immediate and long -term benefits for p articipating practices 
and providers include develop ment of  effective and efficient vaccine delivery systems and increased  
capability to strongly recommend the HPV vaccine and address the con cerns of hesitant parents. Also, 
their experience in the change process may encourage them to identify and address other care gaps in 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
13 
 their practice. An immediate benefit for p reteens attending study practices could be receipt of HPV 
vaccine before sexual debut, allowing maximum benefit from this safe vaccine.    
2.3.3 ASSESSMENT OF POTENTIAL RISKS AND BENEFITS  
 
There are essentially no significant  immediate or long -term risks  in study participation. Th e potential 
benefits to society and children from an effective intervention to reduce HPV -related cancers far 
outweigh the potential risks . 
 
 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
14 
 3 OBJECTIVES AND END POINTS  
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  PUTATIVE 
MECHANISMS OF 
ACTION  
Primary  
 To evaluate the effectiveness of 
the intervention to improve 
optimal HPV vaccine use . The proportion of eligible 
preteens who initiate the 
HPV vaccine b efore their 
13th  birthday, at 24 months.  
  
The proportion of eligible 
preteens who complete the 
HPV vaccine before their 
13th  birthday, at 24 months.  
  Consistent with CDC 
Guideline Recommendations     
Secondary  
 To assess the sustainability of 
intervention benefit .  The proportion of eligible 
preteens who initiate the 
HPV vaccine before their 
13th  birthday, at 36 months.  
  
  
The proportion of eligible 
preteens who complete the 
HPV vaccine before their 
13th  birthday, at 36 months.  
     
Tertiary/Exploratory  
 To determine whether the 
intervention effect on vaccination outcomes is mediated by providers’ increased belief in their 
capabilities to provide on -time 
HPV vaccination (primary 
outcome) and by their increased 
use of a presumptive, 
announcement approach to recommend HPV vaccine 
(secondary ) The proportion of eligible 
preteens who initiate the 
HPV vaccine before their 
13th birthday, at 24 months.  
  
  
The proportion of eligible 
preteens who complete the 
HPV vaccine before their 
13th  birthday, at 24 months . 
 
 
 
 
    Mediation  
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
15 
 OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  PUTATIVE 
MECHANISMS OF 
ACTION  
 
 
  
To e xplore if the intervention 
effect on vaccination outcomes 
is mediated by the degree of practice change as measured on an 18- item HPV vaccine delivery 
score.  
  
To inform scalability of the 
intervention, we will assess implementation fidelity, the acceptability and appropriateness of the intervention for providers, 
parental satisfaction with care, 
and cost.   The proportion of eligible 
preteens who initiate the 
HPV  vaccine before their 
13th birthday, at 24 months.  
  
The proportion of eligible 
preteens who complete the 
HPV vaccine before their 
13th birthday, at 24 months.  
 
 Implementation fidelity, the 
acceptability and 
appropriateness of the 
intervention for provi ders, 
parental satisfaction with 
care, and cost.   Mediation  
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
16 
 4 STUDY DESIGN  
4.1 OVERALL DESIGN  
 
We will complete a single site,  cluster -randomized trial to evaluate the effectiveness of a multi -
component implementation strategy (the intervention) to increase use of the HPV vaccine according to 
CDC guidelines.  Randomization will occur after baseline assessment and the unit of rand omization is a 
community -based, primary care pediatric practice.  The randomization schema will be generated and 
implemented by the study statistician. Twenty practices will be randomized into two groups, the 2 -year 
intervention group (n=10) or a wait -list control group (n=10).  The intervention includes: 1) an 
educational video to increase the provider’s knowledge about guideline recommendations and patient and practice benefits of vaccination by age 13; 2) audit and feedback of vaccine coverage to increas e 
motivation to engage in practice change; 3) a communication strategy to improve the provider’s 
communication skills and their self -efficacy to address parental hesitation; and 4) practice facilitation to 
support practice change to develop a sustainable H PV vaccine delivery system. The intervention will be 
delivered through a series of brief practice visits  with the facilitator that occur every 1 -4 weeks over 2 
years.  Vaccine use will be assessed at the practice  level using 12 -months of routinely collected  clinical 
data to allow for seasonal variation in care delivery patterns. Vaccine use will be assessed at baseline, at 
12 and 24 months to assess effectiveness, and at 36 months to assess if change is sustained.  Due to the 
2020 pandemic and overall concer ns for safety, we will use ZOOM video conferencing for research 
activities, including obtaining measures and implantation of the intervention  
 
The study hypotheses are : 1) The 2 -year intervention will increase the percentage of preteens who 
receive HPV va ccine before their 13
th birthday by at least 13 percentage points, and benefits will be 
sustained at 36 months. 2) The intervention will increase on -time HPV vaccination by increasing 
providers’ capability (communication skills) and their motivation (confidence in their capabilities) to 
deliver  on-time HPV vaccination . 
 
4.2 SCIENTIFIC RATIO NALE FOR STUDY DESIG N 
 
A rigorous evaluation such as the prop osed cluster randomized controlled trial is needed to establish the 
effectiveness of the intervention in a generalizable sample prior to scaling for widespread use. 
Randomization will be at the level of the practice for two reasons: 1) the intervention is designed to 
change the system for adolescent vaccine delivery at the practice level, and 2) to prevent contamination 
of provider behavior within the same practice. The 3 -year follow -up required for assessment of 
sustained change , a key consideration prior to widespread dissemination, precluded a stepped wedge 
design.  
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
17 
 Practices will be recruited from community pediatric practices in the St. Louis metropolitan area and are 
representative  of independent practices where vaccination typically occurs. Our sample size of 20 
practices (~80 providers) allows us to test the primary hypothesis and provide interpretable results.   All 
providers (intervention and control groups) will receive informat ion provided by the CDC to assist 
motivated providers who want to improve use of HPV vaccine that are representative of “usual care.” These will include the current recommendations, background information and the CDC’s patient 
educational materials and web site.  The wait- list control group will be offered the intervention after the 
evaluative study is completed. Initiation of HPV vaccine by age 13 is the primary outcome as local 
providers suggested this is the most difficult barrier to overcome to achieve op timal use of this effective 
vaccine. Vaccine outcomes will be assessed at the clinic level using 12 -months of routinely collected 
clinical data to allow for seasonal variation in care delivery patterns (the majority of check -up visits 
occur in the summer).  This measurement approach is characteristic of quality metrics and is needed to 
show change in vaccine coverage over time, as the guidelines are age- specific. The outcome assessor 
will be blinded to study group allocation to minimize measurement bias.
 
 
4.3 JUSTIFICATION FO R INTERVENTION  
 
The reasons for under -use and sub -optimal use of HPV vaccine are complex and require an innovative 
solution. A systematic assessment of the HPV vaccination process identified  that the barriers to use 
were related to provider and practice characteristics. We developed a multi -component intervention 
designed to simultaneously address all these factors. Previous research has shown that interventions to 
change physician behavior a re most effective if they are based on national guidelines, address specific 
barriers to change, and include several components.49,50 The proposed intervention is based on CDC 
guidelines, addresses specific barriers to HPV vaccine use in primary care pract ices, and has multiple 
components. It is informed by the Theoretical Domain Framework, a behavioral change theory specific 
for primary care providers, and has been refined by pilot testing. It is designed for sustainability, using 
practice facilitation to support practice change, allowing 2 years for sustained change to occur.  
Preliminary testing suggest the intervention is effective, acceptable to providers and ready for 
community -level testing.  
 
 
4.4 END -OF-STUDY DEF INITION  
 
Intervention practices are considered to have completed the study after the baseline, 12 -, 24- and 36 -
month measurements for vaccine coverage have been collected.   Control practices may continue for an 
additional 24 months to receive the  intervention.  
 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
18 
 5 STUDY POPULATION  
5.1 INCLUSION CRITER IA 
IN ADDITION TO PROVIDING APPROPRIATE CONSENT , PRACTICES AND INDIVIDUALS MUST 
MEET THE FOLLOWING I NCLUSION CRITERIA TO  PARTICIPATE IN THE STUDY. FOR EACH 
GROUP OF STUDY SUBJE CTS, PARTICIPATION IS OPEN TO ALL, INCLU DING ANY GENDER 
AND RACIAL AND ETHNIC GROUP.  
 
Practice  Providers   Adolescents  
Community -based 
pediatric primary care 
practices with 2 or 
more providers  Providers who deliver 
wellness care to 
preteens and 
adolescents   Adolescents 10 -13 
years of ag e during the 
measurement period   
Practice in St. Louis 
metropolitan area  Willingness to 
complete study 
questionnaires   At least one visit  during 
the measurement period  
Willingness to 
participate in the practice facilitator-
guided QI process  Willingness to 
participate in the 
practice facilitator-
guided QI process    
    
 
 
 
5.2 EXCLUSION CRITER IA 
 
Practices, providers and parent/caregivers may be excluded at the discretion of the PI .  Our plan is to 
exclude practices that are solo -practitioners and that have paper records. If we have difficulty recruiting, 
we may include these practices.   
 
 
5.3 LIFESTYLE CONSID ERATIONS  
N/A 
 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
19 
 5.4 SCREEN FAILURES  
N/A 
 
5.5 STRATEGIES FOR R ECRUITMENT AND RETEN TION  
 
Practices : We will invite all potentially eligible practices that are affiliated with WU PAARC and 
Community Outpatient Practice Experience (COPE) to participate. The first 20 practices that agree to 
participate will be randomly assigned to the intervention or control group using an allocation ratio 1:1.              
 
Practices may be contacted by email, f ax, letter, phone, or in -person to invite participation.  All 
providers in the practice will be invited to participate. Dr. Garbutt and/ or a member of the study team 
will meet with those who are interested in learning more about the study to explain the d etails of study 
participation and answer any questions. These meetings will be held at the provider’s office. If we experience difficulty with recruitment, we may expand our criteria to include solo practitioners and 
practices who still maintain paper reco rds, as well as practices in the community that are not affiliated 
with WU PAARC or COPE.   
 We anticipate that we will recruit ~80 primary care pediatricians from the  20 participating practices. We 
estimate the racial/ethnic breakdown of participating physicians based on surveys completed by members of our PBRN, the available study population. We estimate that 27% of participating physicians 
will be male, ~84% will be Caucasian, 6% African American , 7% Asian. About 6% will be Hispanic.  
Due to the 2020 Coronavirus pandemic, the baseline parent survey was  eliminated . Changes in EMR 
protocols has made parent contact information inaccessible, therefore the electronic paren t survey has 
been completely eliminated from the study.  The goal of this survey, to assess if parental satisfaction 
with HPV vaccine care differed between study groups, will be met by adding questions to the provider 
survey. Specifically, to assess provide r experiences with patient complaints and loss to the practice 
related to HPV vaccine delivery, repeating the measure from the baseline provider survey.  
 
 
Incentives:   We will provide financial compensation for time taken to participate in the study 
including  $500/year for the business entity of each participating practice for administrative expenses 
(obtaining the lists of eligible patients, allowing study team access to medical records, etc.). We will also 
provide $50 for providers who complete study surveys.   
 We will provide opportunity for all participating pediatricians to earn American Board of Pediatrics (ABP) Maintenance of Certification (MOC)  Part-4 credit to m aintain board certification in general pediatrics. To 
accomplish this, pediatricians must be up to date in four areas including professional standing (part 1), lifelong learning (part 2), cognitive expertise (part 3) and improving professional practice (pa rt 4). Every 
5 years, each pediatrician is required to earn 100 points through part 2 and part 4 activities, with 40 -60 
points for each part. Part 4 activities require pediatricians to demonstrate competence in systematic 
measurement and improvement in pat ient care work that is intended to improve child health. Our 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
20 
 project is approved by the American Board of Pediatrics and is sponsored by Saint Louis Children’s 
Hospital, Washington University School of Medicine, and meets requirements for part 4 activities . To 
earn MOC -credit, the pediatrician must participate in the intervention  for at least 12 -months.  
  
We will consult with our 6 -member Advisory Board of key stakeholders (pediatricians, pediatric nurse 
practitioners and parents) to receive their advice about strategies to increase recruitment and retention 
of practices.  
 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
21 
 6 STUDY INTERVENTION(S) OR EXPERIMENTAL MA NIPULATION(S)  
6.1 STUDY INTERVENTI ON(S) OR EXPERIMENTA L MANIPULATION(S) AD MINISTRATION  
6.1.1 STUDY INTERVEN TION OR EXPERIMENTAL  MANIPULATION DESCRIPTION  
The intervention occurs at the level of the practice.  
 
All providers (intervention and control groups) will receive information provided by th e CDC to assist 
providers to improve use of HPV vaccine  including  the current recommendations, background 
information about the vaccine, and  patient educational materials . The CDC  website will be distributed.  
Baseline HPV vaccination rates will also be giv en to all providers.  
 
The intervention:  
The theory -based, multicomponent intervention includes: 1) an educational video to increase the 
provider’s knowledge about guideline recommend ations and patient and practice benefits of 
vaccination by age 13; 2) audit and feedback of vaccine coverage to increase motivation to engage in 
practice change; 3) a communication strategy to improve the provider’s communication skills and their 
self-efficacy to address parental hesitation; and 4) practice facilitation to support practice change to 
develop a sustainable HPV vaccine delivery system. The intervention is based on CDC guidelines, 
addresses specific barriers to HPV vaccine use in primary care p ractices, and has multiple components. It 
is informed by the Theoretical Domain Framework, a behavioral change theory specific for primary care providers, and has been refined by pilot testing.  We anticipate that the intervention will increase on -
time HPV vaccination by increasing providers’ capability (communication skills) and their motivation 
(confidence in their capabilities) to deliver  on-time HPV vaccination . 
 
The intervention  is designed for sustainability, using practice facilitation to support lasting practice 
change.  It will  be delivered through a series of brief practice visits with the facilitator that occur every 1 -
4 weeks over 2 years.    The usual care control group will be offered the intervention after the evaluative 
study is completed.   Visits will be completed either in -person or through  zoom video conferencing if 
face -face visits are not possible.   
6.1.2 ADMINISTRATION  AND/OR DOSING  
 
Practice facilitation comprises on -site visits by the facilitator to meet with providers and/or staff.  The 
schedule of visits is tailored to the practice but generally  visits  occur  twice in the first month (to make a 
practice assessment) and then weekly to monthly thereafter (to effect practice change, provide 
education etc), with the goal of practice provi ders and staff working together to enhance their ability to 
deliver on -time HPV vaccination and encouraging persistence in the change process. Additional support 
via telephone and/or email will be available. Our own experience and reports in the literature31, 63 
support the need for an extended time period for the change process to occur, with multiple PDSA 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
22 
 cycles. Practices will need time to expand their clinical focus to a population -based approach to identify 
and vaccinate eligible preteens who do not at tend for a check -up visit.31 Strategies to identify and recall 
these patients will be new for many practices and include  software, EMR features and staff outreach. In 
addition, completion of the vaccine series requires 6 to 12 months. Thus, practices will have access to 
the practice facilitator and intervention components for 2 years, including two “well -child” seasons, a 
time when providers in the pilot study reported it was easier to access the target age group and 
experiment with changes to HPV vaccine d elivery.  
 
 
 
 
 
Table 2. Roll -out of the intervention  
Month 1   
Visit  Activities  
Visit 1  
Led by:  
Practice Facilitator and 
Principal Investigator 
and/or Project 
Coordinator  
(30-45 mins)  
  Review project goals  
 Identify overall practice goals  
 Introduce intervention components  
 Introduce practice facilitator and review facilitation process  
 Identify potential members for practice QI team  
 Introduce practice assessment process  
 
Practice Assessment  
with practice providers, 
practice manager, and/or 
staff involved in vaccine 
process  
Led by:  
Practice Facilitator  Understand provider and practice processes for giving HPV vaccine  
 Understand practice workflow  
 Learn individual provider goals for project  
 Ask providers to participate in education by watching video  
Visit 2  
Led by:  
Practice Facilitator 
(30-45 mins)  
  Review baseline HPV vaccination rates for practice/U.S.  
 Synthesize current HPV vaccination practices, provider individual project goals, and  
practice goals  
 Discuss potential opportunities for improvement  
 Establish practice goals for initiation and completion  
 Decide focus for initial change idea targeting initiation  
 Identify resources needed to accommodate change  
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
23 
 Month 2   
Visit 3  
Led by:  
Practice Facilitator           
(30-45 mins)  
(no more than 2 -3 weeks 
after Visit 2)   Determine first PDSA cycle to accomplish change idea  
 Identify process needed to accommodate change  
 Identify resources needed to accommodate change  
 Decide how to monitor change  
 
Month 3 – 2 Years   
Subsequent visits during 
change process  
Bi-weekly/monthly visits for 
2 years  
(15-45 mins)  
  Review success with PDSA cycle(s) and determine next steps  
 Review considerations to implement change ideas  
 Determine process for implementing change ideas and PDSA cycles  
 Support practice QI team and efforts to make changes  
 Provide education and skills training for providers and staff such as communication 
strategy, HPV vaccine, parental talking points, etc . 
 Assist with self -monitoring of HPV vaccination to assess progress  
 Assist with measurement for PDSA cycles  
 Provide social support  
 Share other primary care practices’ best practices and change ideas  
 Provide education for providers and staff about  QI methods  
Subsequent visits for 
Maintenance  
Led by:  
Practice Facilitator 
(check in every 2 weeks to 
monthly for 3 months)   Continue monitoring practice to check for sustainability  
 Work with practice to trouble shoot any changes or procedures as neede d 
 Make sure the practice has access to all resources and tools as needed  
 Provide process for obtaining MOC -Part 4 credits  
 
 
6.2 FIDELITY  
6.2.1 INTERVENTIONIS T TRAINING AND TRACK ING  
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
24 
 Ms. Dodd is responsible for training the practice facilitators, and for their supervision throughout the 
study period.  Training is based on the AHRQ Practice Faci litator training and modules, accepted by the 
University of Buffalo Practice Facilitation Program.  
 
Fidelity criteria were developed by the study team based on a literature review, best practices for 
facilitation 71, 72 and our experiences using facilitat ion in the pilot study. Every 12 -months, use of the 
core components will be  assessed and  recorded by Ms. Dodd  using a 23 -item observational measure 
(Table 3). All items will be scored on a 2 -point scale ( yes/no ) or a percentage basis. 73 We will also track  
the time to achievement of key implementation milestones by noting dates of completion of specific 
activities (such as completion of provider education).74 The facilitators will record the number and 
duration of visits to the practice, number of QI team m eetings and attendees, and PDSA cycles 
undertaken. To supplement these measures, guide the intervention and assess the intensity of the 
facilitation process, the facilitator will keep detailed field notes about practice  observations and 
interactions that w ill be reviewed with Ms. Dodd at weekly meetings.    
 
Table 3. Fidelity Score  
HPV Vaccine Project Fidelity Score  Adherenc
e Dose  
Audit and Feedback  Yes No   
Baseline data summary report is available        
Facilitator provides practic e data and de -identified 
provider- level data to the QI team.      QI team reviews 
practice 
baseline data.  Y/N 
Facilitator provides identified individual data to each 
provider      Providers who 
review own 
baseline data.  % 
Facilitator encourages reflection and critical assessment of 
current practice and identification of performance gap(s).        
        
Provider/Staff education  Yes No   
Facilitator reviews guideline recommendation for "on 
time" H PV vaccine with QI team.  
    Providers 
participate in 
education/training about “on-time” HPV vaccination 
(video, other).  % 
Facilitator reviews rationale for age target wit h QI team.        
Facilitator provides educational resources to practices 
including guideline recommendations, videos, manuscripts.      HPV vaccine 
training provided to 
staff.  Y/N 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
25 
         
Communication Strategy  Yes No   
Facilitator educates providers and staff about the four key 
elements of the communication strategy.      Providers and 
key staff receive 
education re 4 
key elements.  P=
% 
S=
% 
Facilitator provides communication training opportu nities 
for providers and staff.  
    Providers and 
key staff 
participate in 
communication strategy training.  P=
% 
X 
RN 
&  
X 
PM 
 
    Number of 
PDSA cycles 
targeting 
communication 
strategy.  # 
        
Practice Facilitator to support using QI methods to effect 
change  Yes No   
Facilitator meets individually with providers and practice 
manager.      Providers who 
meet with PF for baseline 
assessment.  % 
 Meet with 
practice manager and/or staff for baseline 
assessment.  Y/N 
Facilitator completes flow diagram summarizing current 
care, integrating baseline assessment and chart review 
data.        
Facilitator presents flow diagram summary to QI team.  
    QI team 
members who review flow diagram 
summary.  % 
    
Core QI team comprises providers and staff.      Providers on 
initial QI team.  % 
     
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
26 
 HPV Vaccine Project Fidelity Score  Adherenc
e Dose  
PF to support using QI methods to effect change (cont.)  Yes No   
Additional  staff included as needed  
    QI team 
members who 
remain on team 
for 1 year.  % 
    
Number of QI team meetings in year 1 (count in -person 
visits, virtual meetings).  
  Tota l time spent 
(hours) in QI team meetings for providers, 
staff, and PF.  P= 
S= 
PF= 
Number of additional PF contact with practice/year.      
     
QI team address at leas t 2 change ideas per year to meet 
their targets for ‘ on time ’ delivery of HPV vaccine.  
    Number of 
changes accomplished for initiation and completion (determined by 
QI team).  I= 
C= 
    
QI team identifies metrics to monitor.  
    Number of 
completed measurement reviews of HPV vaccine 
use/year.   
QI team impleme nts system to monitor.        
     
 
Practice Facilitator 
Quality of delivery : score 1 (poor) to 10 (excellent)  Score  
PF ability to identify, assess, and summarize relevant data - consider base line assessment, 
PDSA cycle measures and on -going monitoring   
PF ability to communicate effectively with QI team   
PF ability to encourage interactive problem solving and consensus building  
  
PF ability to encourage a diverse QI team including key pers onnel   
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
27 
 PF ability to encourage and sustain change efforts eg, shares info across practices, 
celebrates etc.   
PF ability to tailor  facilitation  activities  to practice  needs  and circumstances    
 Overall  
6.3 MEASURES TO MINIMIZE  BIAS: RANDOMIZATION  AND BLINDING  
 
Bias:  Although most providers will be from St Louis me tropolitan area, they will be drawn from the bi -
state area. We will gather information to describe participants and eligible non -participants to assess 
selection bias and allow others to assess the relevance of our findings to their situation.   
  
Randomiza tion: We will stratify  practices into 2 -groups by the number of providers.  (< 4 and >  5) We 
will randomize within the strata using a block design.  
  
Blinding:  It is not possible to blind investigators or practices from group assignment. The RA and the 
data analyst will be blinded to group  assignment and are responsible for assessment of the primary and 
secondary outcome measures of HPV  vaccine use. Blinding is not necessary for baseline measurements 
as this will occur prior to randomizati on. Thus, baseline measures may be completed by other members 
of the study team. In addition, measurement bias will be minimized for the assessment of these 
outcomes by using a  standardized approach for data collection and analysis, as well as quality chec ks. 
6.4 STUDY INTERVENTI ON/EXPERIMENTAL MANI PULATION ADHERENCE 
 
The facilitators will record the number and duration of visits to the practice, number of QI team 
meetings and attendees, and PDSA cycles undert aken.  
  
To supplement these measures, guide the intervention and assess the intensity of the facilitation 
process, the facilitator will keep detailed field notes about practice observations and interactions that 
will be reviewed at weekly meetings.  Quality of delivery : score 1 (poor) to 10 (excelle nt) Score  
PF ability to identify, assess, and summarize relevant data - consider baseline assessment, 
PDSA cycle measures and on -going monitoring   
PF ability to communicate effectively with QI team   
PF ability to encourage interactive problem solving a nd consensus building  
  
PF ability to encourage a diverse QI team including key personnel   
PF ability to encourage and sustain change efforts eg, shares info across practices, 
celebrates etc.   
PF ability to tailor  facilitation  activities  to practice  needs  and circumstances    
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
28 
  
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
29 
 7 STUDY INTERVENTION /EXPERIMENTAL MANIPU LATION DISCONTINUATION AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1 DISCONTINUATION OF STUDY INTERVENTIO N/EXPERIMENTAL MANIP ULATION  
 
If new knowledge becomes available regarding the safety or efficacy of the HPV vaccine use, the study 
may be discontinued.   
 
7.2 PARTICIPANT DISC ONTINUATION/WITHDRAW AL FROM THE STUDY  
 
At the discretion of the PI , study participants may be withdrawn for noncompliance.   Providers are free 
to withdraw from participating in the study at any time upon request.  Parent/caregiver participation is 
one-time only with no follow -up and is limited t o completion of one questionnaire.  
 
7.3 LOST TO FOLLOW -UP 
 
N/A  
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
30 
 8 STUDY ASSESSMENTS AND PROCEDURES  
8.1 ENDPOINT AND OTH ER NON -SAFETY ASSESS MENTS  
 
Mixed methods of data collection will be used including audit of the electronic medical record (EMR) to 
extract routinely collected and previously recorded data, surveys, and field note s. The study team will 
follow the same measurement procedures for both study groups.  
 
The primary and secondary outcomes  (vaccine initiation and completion by age 13, respectively) will be 
assessed by audit of the EMR, completed by the research assistant (RA) and/or a member of the study 
team . To assess variation among providers in the same practice, we will sample records from each 
participating provider.  Measurement will be completed over four 12 -month time periods (baseline, 12 , 
24, and 36 months). For  each measurement period, the physician’s office will provide an electronic list 
of eligible patients with an office visit with each participating provider. For each practice , a member of 
the study team will randomly select a sample of 60 records per provi der from this list for review by the 
RA and or other member of the study team. As much as possible the number of r ecords will be balanced 
across providers.  Data abstracted from the record will include date and type of index visit (well child , 
acute care , and other e.g.,  immunization ), date of birth, date of vaccination for HPV vaccine, Tdap, and 
MCV, sex, race/ethnicity and insurance status. Records will be de -identified for patient, provider and 
practice identifiers, and given a unique subject ID number.  
Providers:  At baseline and at 12 - and 24 -months, in addition to the EMR audit described above, all 
participating providers will complete a brief survey to assess their knowledge, attitudes and behaviors regarding HPV vaccination. The baseline survey will a lso assess demographic and other practices and 
physician -level factors that may affect intervention success and are needed to describe the study 
sample. The practice facilitator will keep detailed field notes about practice observations, contextual 
factors  and practice change components, and will monitor the implementation process.  
Practices: At baseline, the project coordinator  and/or a member of the study team  will meet with the 
practice manager to complete a brief practice survey to describe the practice and current HPV 
vaccination procedures. HPV vaccination procedures will be reassessed in a similar manner at 12 - and 
24- months.  
 
Following the conclusion of the intervention, int ervention practices will be invited to participate in an 
exit interview with the PI  to assess the providers and their staff’s experiences in participating in the 
HPV vaccine intervention, and to get input fro m participants about potential improvements in the 
intervention.  These i nterviews will be audio recorded, consent for recording will be verbal.  
 
 
 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
31 
  8.3 Adverse Events and Serious Adverse Events  
8.3.1 DEFINITION OF ADVERSE EVENTS  
 
The care being provided to patients by participating study  practices is indicated and therefore the only 
potential adverse event is breach of confidentiality. Regular  monitoring will occur and any breach of 
confidentiality  will be reported to the IRB as required  per institutional  guideline s if necessary.  
 
8.4 UNANTICIPATED PR OBLEMS  
8.4.1 DEFINITION OF UNANTICIPATED PROBLE MS 
 
This protocol uses the definition of Unanticipated Problems as defined by the Office for Human 
Research Protections (OHRP). OHRP considers unanticipated problems  involving risks to participants or 
others to include, in general, any incident, experience, or outcome that meets all the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in t he study -related documents, such as the IRB -approved research protocol ; and (b) 
the characteristics of the su bject population being studied.  
• Related or possibly related to participation in the res earch.  
• Suggest s that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.      
8.4.2 UNANTICIPATED PROBLEMS REPORTING  
 
The PI will report unanticipated problems to WU IRB as required per institutional guidelines if n ecessary.  
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
32 
 9 STATISTICAL CONSID ERATIONS  
9.1 STATISTICAL HYPO THESES  
• Primary Efficacy Endpoint(s):  
We hypothesize that t he 2-year  intervention  will increase  the percentage  of preteens  who  receive 
HPV  vaccine  before  their 13th birthday  by at least  13 percentage  points  at 24 months compared to 
control , and benefits  will be sustained  at 36  months.  
 
Alternatively, our null hypothesis is that there will be no difference in HPV vaccine use between the 
intervention and control groups.  
9.2 SAMPLE SIZE DETE RMINATIONS  
 
AIM 1 : We will use a cluster randomized design. Study outcomes will be measured at the level of the 
patient using a cross -sectional design. The sample size determination is based on the primary outcom e - 
initiation of HPV vaccination by age 13. Effectiveness is derived from the difference in the proportion of 
eligible preteens in the intervention and control groups 24 months after the intervention, and long -term 
maintenance is derived from the differen ce in these measures 36 months after intervention. In the 
control group, national data suggest the baseline vaccine initiation proportion should be 0.4. We expect the vaccine initiation proportion in the control group in this age group will not change over  time, and 
intervention group will have a similar baseline initiation rate to the control group, but will increase by at 
least 0.13 by 24 months. Thus, the hypothesis to test is          𝐻𝐻
0: 𝑝𝑝=0.4 vs. 𝐻𝐻 1: 𝑝𝑝=0.53.  
Our study has a three level hierarchica l structure: children are clustered within providers which are 
clustered within practices. Thus, there exists correlations for children seen by the same provider, as well 
as providers working in the same practice. We use random effects to capture the intra -class correlation 
at the provider and the practice levels. From our preliminary data, the estimate for random effect variance at the practice level is very close to 0, and that at the provider level is 0.75
2 (corresponding to 
an ICC of 0.15). This suggest s very little heterogeneity at the practice level, but significant heterogeneity 
at the provider level. Since there is no ready -to-use software for power calculation for clustered trial in 
the three level hierarchical structure, we conduct the power calcul ation by simulation.  
In the simulation study, we set 𝜎𝜎𝑎𝑎2=.01 for the random effect at the practice level and 𝜎𝜎𝑏𝑏2=.752 for 
the random effect at the provider level. We choose the value of 𝛽𝛽  so that the proportion of HPV vaccine 
rate is 0.4 for control and 0.53 for the intervention. We assume there are 4 physicians in each practice, each physician sees 30 children, resulting a total of 120 patients in each practice. The sample size to calculate is the number of practices. The simulation study is carried out in R, using function glmer() in 
the mle4  package for estimation of the generalized linear mixed effects model (1) below.  
Our original simulation results showed that 10 practices in the control arm and 10 practices in the 
intervention arm (a total of 1 20*20=2,400 children) would achieve a power over 0.80, to reject the null 
hypothesis under the significance level of 0.05. To address variation in the number of providers/practice, 
and to account for inclusion of more providers than anticipated (95 vs 80),  we have chosen to increase 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
33 
 the sample size to 60 patients/provider, to ensure adequate power to detect a meaningful difference 
between the control group and the intervention group .  
We also considered different baseline initiation rates in the control group in the range of 0.4 to 0.6. Our sample size of 10 practices in each arm has sufficient power to detect a difference in the rate of 0.12 when the baseline rate is 0.5 (i.e., 𝐻𝐻
0: 𝑝𝑝=0.5 vs. 𝐻𝐻1: 𝑝𝑝=0.62), and 0 .12 when the baseline rate is 0.6 
(i.e., 𝐻𝐻0: 𝑝𝑝=0.6 vs. 𝐻𝐻1: 𝑝𝑝=0.72). In summary, the sample size of 20 practices provides adequate 
power to detect a 13% or larger effect.  
To date, the literature suggests increased vaccination in 13 -17 year -olds, but li ttle year -to-year variation 
in vaccine outcomes in 11 -12 year -olds, and so we have assumed no change in control group outcomes 
for our calculations. Finally, we considered the unlikely event of a 5% increase in vaccine initiation in the 
target group. In th is case, our calculations suggest that a sample of 10/group would provide over 80% 
power to detect an 18% increase in the intervention group.  
 
AIM 2 : The joint significance test79 will be used to test if the mediation effect is significant. The p -value 
from the joint significance test is the maximum of the p -values in testing 𝛼𝛼 1=0 and 𝛾𝛾 =0 separately, that 
is, it requires that both 𝛼𝛼 1 and 𝛾𝛾  are significant simultaneously. We thus use a Bonferroni ’s correction to 
set the significance level to be 0.05/2=0. 025 for each test. We expect the power in testing 𝛾𝛾 =0 is lower 
since the outcome is a binary variable, while the mediator is a continuous or categorical variable which can yield more e fficiency and higher power. Thus, we will repeat our simulation study in Aim 1 for power 
calculation, but use the alpha level of 0.025 instead of 0.05. Our sample size of 10 practices in each arm 
has sufficient power to detect a difference in the rate of 0 .14 when the baseline rate is 0.4, and 0.13 
when the baseline rate is 0.5 or 0.6. In summary, the sample size of 20 practices provides adequate 
power to detect a 14% or larger effect.  
 
9.3 POPULATIONS FOR ANALYSES  
 Data  analyses  will adhere  to the intention -to-treat principle,  allowing  12-months  grace  period  to 
implement practice  changes.  The primary analysis  will compare  the overall  proportion  of eligible  
preteens  who  initiated  and completed  HPV  vaccination  in the intervention  and control practices  at 24 
months,  using  Year  2 measurements  for vaccine  use.  Maintenance  of change  will be assessed  using  Year  
3 measurements.   
 
9.4 STATISTICAL ANAL YSES  
9.4.1 GENERAL APPROA CH 
 All main data analyses will adhere to the intention -to-treat principle, and a probability of P < 0.05 will be 
used to establish statistical significance (2 -tailed test).   Before we perform complic ated statistical 
modeling, we will conduct exploratory data analysis. For continuous variables, we will examine their 
distribution, and summarize them with mean/standard deviation if data are reasonably normally 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
34 
 distributed, or with median/interquartile ra nge if data are skewed. We will use Rosner’s outlier 
detection routine. Categorical data will be summarized by proportions. Simple comparison of 
continuous variables between intervention and control group will be performed using two sample t test 
or non -parametric Wilcoxon test.  Simple comparison of categorical variable will be performed using chi -
square test or fisher exact test where appropriate.  
 
9.4.2 ANALYSIS OF TH E PRIMARY ENDPOINT(S ) 
 
Data  analyses  will adhere  to the intention -to-treat principle,  allowing  12-months  grace  period  to 
implement practice  changes.  The primary analysis  will compare  the overall  proportion  of eligible  
preteens  who  initiated  and completed  HPV  vaccination  in the intervention  and control practices  at 24 
months,  using  Year  2 measurements  for vaccine  use. Maintenance  of change  will be assessed  using  Year  
3 measurements.  The analytic  approach  is to use a multi -level random  effects  logistic  model  to account 
for the hierarchical structure:  children  clustered  within  providers  clustered  within  practices.  
 
Define by 𝑦𝑦 𝑖𝑖𝑖𝑖𝑖𝑖 as the binary variable of HPV vaccine for the 𝑖𝑖 th child of provider 𝑖𝑖  of practice 𝑖𝑖 . There are 
3 hierarchical levels: children c lustered within providers clustered within practices. We use random 
effects to capture the intra -class correlation at the provider and the practice levels. We assume a multi -
level random effects logistic model (a generalized linear mixed model):  
    logit  𝑃𝑃(𝑦𝑦𝑖𝑖𝑖𝑖𝑖𝑖=1)=𝛽𝛽0+𝑡𝑡𝑡𝑡𝑡𝑡𝑖𝑖𝑖𝑖𝑖𝑖𝛽𝛽1+𝑎𝑎𝑖𝑖+𝑏𝑏𝑖𝑖𝑖𝑖                                         (1)         
 
where 𝑡𝑡𝑡𝑡𝑡𝑡𝑖𝑖𝑖𝑖𝑖𝑖 is the treatment indicator for practice 𝑖𝑖 , and 𝛽𝛽 1 is the treatment effect. We use random 
effects 𝑎𝑎𝑖𝑖 and 𝑏𝑏𝑖𝑖𝑖𝑖 to describe heterogeneity in the practice level and provider level, and assume 
𝑎𝑎𝑖𝑖∼(0,𝜎𝜎𝑎𝑎2) and 𝑏𝑏 𝑖𝑖𝑖𝑖∼𝑁𝑁(0,𝜎𝜎𝑏𝑏2) are independent. The practice level random intercept is used to 
accommodate extra- variation in outcome measurements due to clustering of pr oviders in a practice, 
and the provider level random intercept is used to accommodate extra -variation in outcome 
measurements due to clustering of individual patients within a provider.  
As secondary analysis, we can add other covariates in the model, e.g.,  gender, category of practice 
(urban vs. rural), vaccine rate at baseline for a provider or practice, etc. Interaction of treatment and 
these covariates can be included in the model to study the moderating effect of these risk factors. The 
interaction of random effects (both at the practice and provider levels) and covariates can be added in 
the model as well.  
 
Missing Data:  As in any other study, we expect some missing data in our stud y. If missing data affects 
the validity of statistical inference, we will follow Little and Rubin to deal with this problem.78 If the 
assumption of “missing at random” holds, this approach will avoid bias and preserves the study power. 
Specifically, multiple imputed completed datasets, say 5, will be generated through parametric (or 
nonparametric) Bayesian models. For each imputed dataset, the standard statistical method is applied 
to obtain the parameter estimates with the estimated variance and covariance. Then, these parameter 
estimates w ith their variance and covariance estimates can be used to generate overall parameter 
estimates and their standard errors.   
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
35 
  
9.4.3 ANALYSIS OF TH E SECONDAR Y END POINT(S ) 
 
 We will use mediation analysis to test whether the provider’s capability and provider’s beliefs about 
their capabilities mediate the intervention’s effect on vaccination outcomes.  
  
 
  
 
       
  
 
 
Define the provider’s beliefs about their capabilities by 𝑀𝑀
𝑖𝑖𝑖𝑖, we can write the model as  
             𝑀𝑀𝑖𝑖𝑖𝑖=𝛼𝛼0+𝑡𝑡𝑡𝑡𝑡𝑡𝑖𝑖𝑖𝑖𝑖𝑖𝛼𝛼1+𝑐𝑐𝑖𝑖+𝑒𝑒𝑖𝑖𝑖𝑖                                                                                                                     (2) 
                                                     logit 𝑃𝑃(𝑦𝑦𝑖𝑖𝑖𝑖𝑖𝑖=1)=𝛽𝛽0+𝑡𝑡𝑡𝑡𝑡𝑡𝑖𝑖𝑖𝑖𝑖𝑖𝛽𝛽1+𝑀𝑀𝑖𝑖𝑖𝑖𝛾𝛾+𝑎𝑎𝑖𝑖+𝑏𝑏𝑖𝑖𝑖𝑖      (3) 
 
We are interested in testing the hypothesis 𝐻𝐻 𝑜𝑜:𝛼𝛼1𝛾𝛾 = 0 vs. 𝐻𝐻 1:𝛼𝛼1𝛾𝛾 ≠ 0. The joint significance tes t79 can be 
used to test the significance of the mediation effect. We include random effect 𝑐𝑐 𝑖𝑖 to capture the 
correlation of the provider’ s capabilities within the same practice. The indirect effect, i.e., the effect of 
intervention to the outcome through the mediator is specified as the product of 𝛼𝛼 1 and 𝛾𝛾. The direct 
effect of treatment on outcome is denoted by 𝛽𝛽 1.  We can use a similar model for provider ’s capability.  
 
Finally, we can also include the interaction of treatment and mediator in Model (3), to test whether the 
mediator is also a moderator of treatment in the “mediator moderator” model.  
 
We will use mediation analysis to tes t whether the intervention effect on vaccination outcomes is 
mediated by the degree of practice change as measured by an 18 -item HPV vaccine delivery score.   
 
For implementation outcomes (fidelity, acceptability, appropriateness), we will complete a descr iptive 
analysis.  Parental satisfaction will be modeled in a three -level (practice, provider, and child’s parent) 
linear mixed effects model .  Descriptive statistics will be given on implementat ion fidelity, the 
acceptability and appropriateness of the intervention for providers, parental satisfaction with care, and 
cost. Of note, f idelity score is measured at the practice level every 6 months in the intervention group 
only. Parental satisfaction  is measured in both study groups at baseline and 24 months.  Provider 
acceptance and appropriateness is measured in intervention group at 24 months.  
 
Denote by 𝑦𝑦𝑖𝑖𝑖𝑖 the fidelity score of practice 𝑖𝑖 at time 𝑡𝑡 . Repeated measures of fidelity score will b e 
modeled by mixed effects models.   
     Indirect: 𝛼𝛼1            
 
 
   
 𝑀𝑀𝑖𝑖𝑖𝑖 
 Indirect:  y 
 
                :  𝛽𝛽1 
 
  
Treatment   
Outcome  Direc t 

HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
36 
 𝑦𝑦𝑖𝑖𝑖𝑖=𝛽𝛽0+𝛽𝛽1𝑡𝑡+𝑎𝑎𝑖𝑖+𝑒𝑒𝑖𝑖𝑖𝑖,      (4) 
 
Where 𝛽𝛽1 is the slope for the temporal change in the fidelity score, 𝑎𝑎𝑖𝑖 is the random intercept for 
practice  𝑖𝑖, and 𝑒𝑒𝑖𝑖𝑖𝑖 is the error term. By testing 𝛽𝛽1=0, we can see if there is a significant increase in the 
fidelity score over time in the intervention group. We can add a random slope of time in this model to 
capture the heterogeneity in such a temporal change.  
 As another example, parental satisfaction wi ll be modeled in a three -level (practice, provider, and child’s 
parent) linear mixed effects model:  
 
𝑦𝑦
𝑖𝑖𝑖𝑖𝑘𝑘=𝛽𝛽0+𝑡𝑡𝑡𝑡𝑡𝑡𝑖𝑖𝑖𝑖𝑘𝑘𝛽𝛽1+𝑎𝑎𝑖𝑖+𝑏𝑏𝑖𝑖𝑖𝑖+𝑒𝑒𝑖𝑖𝑖𝑖𝑘𝑘 
 
For cost, it is beyond the scope of this project to complete a cost -effectiveness analysis that includes all 
long -term related social costs and benefits (e.g., prevention of cancer, reducing costs of secondary 
prevention activities). Rather, we will prospectively as sess the cost to replicate the intervention in 
practice.77 To generalize beyond Missouri, geographic wage data from the Bureau of Labor Statisti cs, 
and average Medicaid allowable rates will establish a minimum on cost reimbursement  
9.4.4 SAFETY ANALYSE S 
 N/A 
9.4.5 BASELINE DESCR IPTIVE STATISTICS  
 
Before  we perform complicated statistical modeling, we will conduct exploratory data analysis. For 
continuous variables, we will examine their distribution, and summarize them with mean/standard 
deviation if data are reasonably normally distributed, or with medi an/interquartile range if data are 
skewed. We will use Rosner’s outlier detection routine. Categorical data will be summarized by 
proportions. Simple comparison of continuous variables between intervention and control group will be 
performed using two samp le t test or non -parametric Wilcoxon test. Simple comparison of categorical 
variable will be performed using chi -square test or fisher exact test where appropriate.  
 
9.4.6 PLANNED INTERI M ANALYSES  
 N/A  
9.4.7 SUB -GROUP ANAL YSES  
 
We plan two subgroup analyses to explore intervention effectiveness for girls and boys, and for those 
with Medicaid insurance compared to other health insurance.  
As secondary analysis, we  can add other covariates in the model used in the primary analysis, e.g., 
gender, category of practice (urban vs. rural), vaccine rate at baseline for a provider or practice, etc. 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
37 
 Interaction of treatment and these covariates can be included in the model to study the moderating 
effect of these risk factors. The interaction of random effects (both at the practice and provider levels) 
and covariates can be added in the model as well.  
 
9.4.8 TABULATION OF INDIVIDUAL PARTICIPA NT DATA  
 N/A 
 
9.4.9 EXPLORATORY AN ALYSES  
 
As secondary exploratory analyses, we can add other covariates in the model used in the 
primary analysis, e.g., gender, category of practice (urban vs. rural), vaccine rate at baseline for a provider or practice, etc. Interaction of treatment and these covariates can be included in the model to study the moderating effect of these risk factors. The interaction of random effects 
(both at the practice and provider levels) and covariates can be added in the model as well . 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
38 
 10 SUPPORTING DOCUME NTATION AND OPERATIO NAL CONSIDERATIONS  
10.1 REGULATORY, ETH ICAL, AND STUDY OVER SIGHT CONSIDERATIONS  
10.1.2 STUDY DISCONT INUATION AND CLOSURE  
 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause. Written notification, documenting the reason for this occurrence will be provided by the 
suspending or terminating party to study practices, the inve stigator, funding agency and regulatory 
authorities.  If the study is prematurely terminated or suspended, the PI will promptly inform 
participating practices, the IRB and NIH, and will provide reasons for the termination or suspension.  
 Circumstances that  may warrant termination or stopping include but are not limited to:  
• Determination of unexpected, significant , or unacceptable risk to participants  
• Insufficient compliance of study staff to the protocol  
• Data that are not sufficiently complete or eval uable  
• Determination that the primary end point has been met  
• Determination of futility  
 
The study may resume once concerns about safety, protocol compliance and data quality area 
addressed, and satisfy the funding agency, sponsor, IRB, FDA, or other reg ulatory or oversight bodies 
such as the IRB.  
 
10.1.6 SAFETY OVERSI GHT  
 
As a safety monitoring committee is n ot required by the NIH for this low risk study, s afety oversight will 
be under the direction of the Principal Investigator. Dr. Garbutt and the Co -Investigators will provide 
study oversight and monitor the conduct of the trial to ensure the safety of the participants and the 
validity and integrity of the data. Responsibilities include: 1)  Review tria l performance information such 
as accrual information, protocol violations, and unanticipated problems  and 2) Review major proposed 
modifications to the study prior to their implementation (e.g., changing target sample size) . They will 
meet at least quarte rly to assess study  progress and safety, and p rovide recommendations related to 
resolving any issues with the trial .  
 
 
 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
39 
 10.3 ABBREVIATIONS A ND SPECIAL TERMS  
Adverse Event  AE 
Agency for Healthcare Research and Quality  AHRQ  
American Board of Pediatrics  ABP 
Centers for Disease Control and Prevention  CDC 
Certificate of Confidentiality  COC  
Clinical and Translational Science Award  CTSA  
Code of Federal Regulations  CFR 
Consolidated Framework for Implementation Research  CFIR  
Consolidated Standards of Reporting Trials  CONSORT  
Data Coordinating Center  DCC 
Data Safety Monitoring Board  DSMB  
Designing for Dissemination  D4D  
Electronic Case Report Forms  eCRF  
Electronic Medical Record  EMR  
Ethics Committee  EC 
Food and Drug Administration  FDA 
Good Clinical Practice  GCP 
Health Insurance Portability and Accountability Act  HIPAA  
Healthcare Effectiveness Data and Information Set  HEDIS  
Human Papilloma Virus  HPV  
Independent Safety Monitor  ISM 
Institutional Review Board  IRB 
International Council on Harmonisation  ICH 
Maintenance of Certification  MOC  
Manual of Procedures  MOP  
Meningococcal V accine  MCV  
National Clinical Trial  NCT 
National Health and Nutrition Examination Survey  NHANES  
National Institutes of Health  NIH 
Office for Human Research Protections  OHRP  
Plan -Do-Study -Act  PDSA  
Practice Based Research Network  PBRN  
Principal Investigator  PI 
Quality Assurance  QA 
Quality Control  QC 
Quality Improvement  QI 
Randomized Control Trial  RCT 
Research A ssistant  RA 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
40 
 Research Electronic Data Capture  REDCap  
Safety Monitoring Committee  SMC  
Schedule of Activities  SOA  
Serious Adverse Event  SAE 
Standard Operating Procedure  SOP 
Statistical Analysis Plan  SAP 
Statistical Analysis software  SAS 
Tetanus -Diphtheria -Pertussis  Tdap  
Theoretical Domains Framework  TDF 
Unanticipated Problem  UP 
United States  US 
Washington University  WU 
Washington University School Of Medicine   WUSM  
Washington University Pediatric and Adolescent Ambul atory Research Consortium  WUPAARC  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
41 
 10.4 PROTOCOL AMENDMENT H ISTORY  
Version  Date  Description of Change  Brief Rationale  
 
 1.02  
   12/20/2019  
   Section 6.3: Blinding not needed for 
assessment of baseline measures  Baseline measures are completed 
prior to randomization.   
Section 10.1.6 :  PI will be responsible 
for safety oversight rathe r than a safety 
monitoring committee  The study is assessed as low risk 
and a safety monitoring 
committee is not required by the 
NIH.  
 
 1.03  1/10/2020   Sections 5.5 and 8.1: Removed #30 
from the eligible sample list for parent 
surveys.   To obtain 30  parents/practice, we 
will need to invite a larger list of eligible parents.  
 
 1.04  
   2/10/2020  
  Sections 1.1 and 6.11: Added, all 
providers will receive baseline HPV 
vaccination rates.  In order to allow all providers to 
know the results of chart audits .  
Section 6.3: Added stratification to the 
block design for randomization.  To balance the randomization 
process for number of providers 
in the practice.   
    
1.05  3/24/2020  Section 5.5 and 8.1: Clarified who will 
send an email or text invitation for study participation to parents.  The email or text invitation will 
come from the study team, providers have the option to send  
an email or text to the parents.  
1.05  3/24/2020   Section 1.2: Study Sch ema to reflect 
measurement for 160 preteens per practice  To maintain power and address 
the variability in the recruited practices (2 -8 providers), we 
increased the sample size of 
patients.  
 
 
 1.05  3/24/2020  Section: 8.1 and 9.2: Increased sample 
size to 160 patients/practice.  To maintain power and address the 
variability in the recruited practices 
(2-8 providers).  
 
    
1.06      5/13/2020                  Eliminated the parent survey at baseline.  Due to the 2020 outbreak of 
Covid -19, it is not possible to 
obtain the necessary information 
for a parent survey at this time.  The survey asks parents to recall 
their  
well -child visit for 2019, which 
would not be useful data at this 
time, and could add stress  on to 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
42 
 the providers.  
 
1.06       5/13/2020                 Added research study activities may be 
delivered by Zoom video conferencing.  Due to the 2 020 outbreak of 
Covid -19, we included Zoom 
video conferencing as a way to 
implement study activities.  
 
 
1.07                     1/25/22   Increased sample size to 60       
               patients/provider   Due to the participation of more 
providers than anticipated (95 vs 80) 
and because of variation among 
providers, our statistician has 
suggested to increase the sample size 
to 60 patients per provider to allow the power to detect a meaningful difference bet
ween the control group 
and intervention group.  
 
1.08  
 
   6/22/2022  Eliminated the parent survey from the 
study .  
    
 Due to restrictions with obtaining 
parent email addresses from the EMR 
and individual practices it is not feasible to complete the parent survey.  
1.3,  8.1                 
     8/26/2022  Added the exit interview for the 
intervention practices.   
    
 To assess the providers and their 
staff’s experiences in participating in 
the HPV vaccine intervention, and to 
get input from participants about 
potential improvements in the 
intervention. . 
   
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
43 
 11 REFERENCES  
1. Petrosky  EY, Liu  G, Hariri  S, Markowitz  LE. Human  Papillomavirus  Vaccination  and Age at First  
Sexual  Activity,  National  Health  and Nutrition  Examination  Survey.  Clin Pediatr  (Phila).  
2017;56(4):363- 370.  
2. Walker TY,  Elam -Evans  LD, Yankey  D, et al. National,  Regional,  State, and Selected  Local 
Area  Vaccination  Coverage  Among  Adolescents  Aged  13–17 Years —United  States,  2017.  
Morbidity  and Mortality  Weekly  Report.  2018;67(33):909.  
3. Healthy  People  2020.   http://healthypeople.gov . Accessed  April  20, 2015.  
4. Chesson  HW, Ekwueme DU, Saraiya M, Dunne  EF, Markowitz  LE. The estimated  impact of 
human  papillomavirus  vaccine  coverage  on the lifetime  cervical cancer  burden  among  girls 
currently  aged  12 years  and younger  in the United  States.  Sexually  transmitted  diseases.  
2014;41(11):656- 659.  
5. Markowitz  LE, Dunne  EF, Saraiya M, et al. Human  papillomavirus  vaccination: 
recommendations  of the Advisory  Committee  on Immunization  Practices  (ACIP).  Morbidity  
and Mortality  Weekly  Report:  Recommendations  and Reports.  2014;63(5):1- 30. 
6. Walker TY,  Elam -Evans  LD, Singleton  JA, et al. National,  Regional,  State,  and Selected  Local 
Area  Vaccination  Coverage  Among  Adolescents  Aged  13-17 Years  - United  States, 2016.  
MMWR  Morb  Mortal  Wkly  Rep.  2017;66(33):874- 882.  
7. Stokley  S, Jeyarajah  J, Yankey  D, et al. Human  papillomavirus  vaccination  coverage  among  
adolescents,  2007– 2013,  and postlicensure  vaccine  safety  monitoring, 2006– 2014—
United  States.  Morbidity  and Mortality  Weekly  Report.  2014;63(29):620- 624.  
8. Chesson  HW, Ekwueme  DU, Saraiya M, Watson  M, Lowy  DR, Markowitz  LE. Estimates  of the 
annual  direct medical costs  of the prevention  and treatment of disease  associated  with  
human  papillomavirus  in the United  States.  Vaccine.  2012;30(42):6016- 6019.  
9. Fu LY, Bonhomme  L-A, Cooper  SC, Joseph  JG, Zimet GD. Educational  interventions  to increase  
HPV  vaccination  acceptance: a systematic  review.  Vaccine.  2014;32(17):1901- 1920.  
10. Edwards  KM, Hackell  JM, Diseases  CoI, Practice  Co, Medicine  A. Countering  vaccine  hesitancy.  
Pediatrics.  2016:e20162146.  
11. Gilkey  MB, Calo  WA,  Marciniak  MW, Brewer  NT. Parents  who  refuse  or delay  HPV  vaccine:  
Differences  in vaccination  behavior,  beliefs, and  clinical  communication  preferences.  Human  
vaccines  & immunotherapeutics.  2017;13(3):680- 686.  
12. Smulian  EA, Mitchell  KR, Stokley  S. Interventions  to increase  HPV  vaccination  coverage: A 
systematic  review.  Hum  Vaccin  Immunother.  2016;12(6):1566- 1588.  
13. Niccolai LM,  Hansen  CE. Practice - and Community -Based  Interventions  to Increase  
Human  Papillomavirus  Vaccine  Coverage: A Systematic  Review.  JAMA  pediatrics.  
2015;169(7):686- 692.  
14. Walling  EB, Benzoni  N, Dornfeld  J, et al. Interventions  to improve  HPV  vaccine  uptake:  a 
systematic  review.  Pediatrics.  2016;138(1):e20153863.  
15. Brewer  NT, Hall  ME, Malo  TL, Gilkey  MB, Quinn  B, Lathren  C. Announcements  Versus  
Conversations  to Improve  HPV  Vaccination  Coverage:  A Randomized  Trial.  Pediatrics.  
2017;139(1).  
16. Paskett ED, Krok -Schoen  JL, Pennell  ML, et al. Results  of a Multilevel  Intervention  Trial  to 
Increase  Human  Papillomavirus  (HPV)  Vaccine  Uptake  among  Adolescent Girls.  Cancer  
Epidemiol  Biomarkers  Prev. 2016;25(4):593- 602.  
17. Zimmerman  RK, Moehling  KK, Lin CJ, et al. Improving  adolescent  HPV  vaccination  in a 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
44 
 randomized  controlled  cluster trial using  the 4 Pillars  practice  Transformation  Program.  
Vaccine.  2017;35(1):109- 117.  
18. Fiks AG, Grundmeier RW, Mayne  S, et al. Effectiveness  of decision  support  for families, 
clinicians,  or both  on HPV  vaccine  receipt.  Pediatrics.  2013;131(6):1114- 1124.  
19. Perkins  RB, Zisblatt  L, Legler A,  Trucks  E, Hanchate  A, Gorin SS. Effectiveness  of a provider -
focused  intervention  to improve  HPV  vaccination  rates  in boys  and girls.  Vaccine.  
2015;33(9):1223- 1229.  
20. Gilkey  MB, McRee  AL. Provider  communication  about  HPV  vaccination: A systematic  
review.  Hum  Vaccin  Immunother.  2016;12(6):1454- 1468.  
21. Dempsey  AF, Pyrznawoski  J, Lockhart S, et  al. Effect  of a health  care  professional 
communication  training  intervention  on adolescent  human  papillomavirus  vaccination:  A 
cluster randomized  clinical  trial.  JAMA  pediatrics.  2018:e180016.  
22. Holman  DM,  Benard  V, Roland  KB, Watson  M, Liddon  N, Stokley  S. Barriers to human  
papillomavirus  vaccination  among  US adolescents:  a systematic  review  of the literature.  
JAMA  pediatrics.  2014;168(1):76- 82. 
23. Perkins  RB, Clark  JA. What  affects  human  papillomavirus  vaccination  rates?  A qualitative  
analysis  of providers' perceptions.  Women's  health  issues  : official publication  of the Jacobs  
Institute  of Women's  Health.  2012;22(4):e379- 386.  
24. National  Ambulatory  Medical Care  Survey  – Community  Health  Centers:  2012 State  and 
National  Summary  Tables.  2012;  
https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2012_namcs_chc_web_tables.pdf
Accessed  3/9/18.  
25. Freed  GL, Moran  LM, Van KD, Leslie  LK, Pediatrics  RACotABo. Current  workforce  of 
general  pediatricians  in the United  States.  Pediatrics.  2016;137(4):e20154242.  
26. Hough  DE, Liu K, Gans  DN. Size matters: the impact  of physician  practice  size on productivity.  
Unpublished  manuscript Medical Group  Management Association (CO). 2011.  
27. Solberg  LI. Improving  medical practice:  a conceptual  framework.  The Annals  of Family  Medicine.  
2007;5(3):251- 256.  
28. Crabtree  BF, Nutting  PA, Miller  WL, et al. Primary  care  practice  transformation  is hard  
work:  insights  from  a 15-year  developmental program of research.  Medical care.  
2011;49(Suppl):S28.  
29. Stange  KC, Goodwin  MA, Zyzanski  SJ, Dietrich  AJ. Sustainability  of a practice -individualized  
preventive  service  delivery  intervention.  American  journal  of preventive  medicine.  
2003;25(4):296- 300.  
30. Martin  J, Avant  R, Bowman  M, et al. The Future  of Family  Medicine:  a collaborative  project of 
the family  medicine  community.  Annals  of family  medicine.  2004;2(2 Suppl 1):S3- 32. 
31. Nutting  PA, Crabtree  BF, Stewart  EE, et al. Effect  of facilitation  on practice  outcomes  in the 
National  Demonstration  Project model of the patient -centered  medical home.  The Annals  
of Family  Medicine.  2010;8(Suppl  1):S33 -S44.  
32. Dickinson  WP, Dickinson  LM, Nutting  PA, et al. Practice  facilitation  to improve  diabetes  care  
in primary  care:  a report from the  EPIC  randomized  clinical trial.  The Annals  of Family  
Medicine.  2014;12(1):8- 16. 
33. Miller  WL, Crabtree  BF, Nutting  PA, Stange  KC, Jaén  CR. Primary care  practice  
development: a relationship -centered  approach.  The Annals  of Family  Medicine.  
2010;8(Suppl 1):S68- S79. 
34. McNellis  RJ, Genevro  JL, Meyers  DS. Lessons learned  from the study  of primary care  
transformation.  In: Annals  Family  Med;  2013.  
35. Goodson  P, Smith MM,  Evans  A, Meyer  B, Gottlieb  NH. Maintaining  prevention  in practice: 
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
45 
 survival of PPIP  in primary care  settings.  American Journal  of Preventive  Medicine.  
2001;20(3):184- 189.  
36. Wei EK, Ryan  CT, Dietrich  AJ, Colditz  GA. Improving  colorectal  cancer screening  by 
targeting  office  systems  in primary  care  practices:  disseminating  research  results  into 
clinical practice.  Archives  of internal  medicine.  2005;165(6):661- 666.  
37. Dietrich  AJ, O'Connor  GT, Keller  A, Carney  PA, Levy  D, Whaley  FS. Cancer:  improving  early  
detection  and prevention. A community  practice  randomised  trial.  Bmj.  1992;304(6828):687-
691.  
38. Dietrich  AJ, Olson  AL, Hill Sox C, Woodruff  Winchell  C, Grant -Petersson  J, Collison  DW.  
Sun protection  counseling  for children: primary  care  practice  patterns  and effect  of an 
intervention  on clinicians.  Archives  of family  medicine.  2000;9(2):155.  
39. Goodson  P, Gottlieb  NH, Smith  MM.  Put prevention  into practice.  American journal  of 
preventive  medicine.  1999;17(1):73- 78. 
40. Goodwin  MA, Zyzanski  SJ, Zronek  S, et al. A clinical trial of tailored  office  systems for 
preventive  service  delivery.  American  journal of preventive  medicine.  2001;21(1):20-
28. 
41. Bordley  WC, Margolis  PA, Stuart J, Lannon C, Keyes  L. Improving  preventive  
service  delivery  through office  systems.  Pediatrics.  2001;108(3):e41- e41.  
42. Damschroder  LJ, Aron  DC, Keith  RE, Kirsh  SR, Alexander  JA, Lowery JC. Fostering  
implementation  of health  services  research  findings  into practice:  a consolidated  framework  
for advancing  implementation  science. Implement Sci.  2009;4:50.  
43. Cane  J, O'Connor D, Michie  S. Validation  of the theoretical  domains  framework  for use in 
behaviour  change  and implementation  research. Implement Sci.  2012;7:37.  
44. Atkins  L, Francis  J, Islam R,  et al. A guide  to using  the Theoretical Domains  Framework  of 
behaviour  change  to investigate  implementation  problems.  Implement Sci.  2017;12(1):77.  
45. Michie  S, Johnston  M, Abraham C, et al. Making  psychological theory useful  for implementing  
evidence  based  practice: a consensus  approach.  Qual  Saf Health  Care.  2005;14(1):26- 33. 
46. French SD, Green  SE, O'Connor  DA, et al. Developing  theory -informed  behaviour  change  
interventions  to implement evidence  into practice:  a systematic  approach  using  the 
Theoretical  Domains  Framework.  Implement Sci.  2012;7:38.  
47. Garbutt JM, Dodd  S, Walling  E, Lee  AA, Kulka  K, Lobb  R. Theory -based  
development  of an implementation  intervention  to increase  HPV vaccination  in 
pediatric  primary  care  practices.  Implementation Science.  2018;13(1):45.  
48. Garbutt JM, Dodd  S, Walling  E, Lee  AA, Kulka  K, Lobb  R. Barriers  and facilitators  to HPV  
vaccination  in primary  care  practices:  a mixed  methods  study  using  the Consolidated  
Framework for Implementation  Research. BMC  family  practice.  2018;19(1):53.  
49. Davis  DA, Taylor -Vaisey  A. Translating  guidelines  into practice:  a systematic  review  of 
theoretic  concepts,  practical  experience and research  evidence  in the adoption  of clinical 
practice  guidelines.  Canadian  Medical Association  Journal.  1997;157(4):408- 416.  
50. Greco  PJ, Eisenberg  JM. Changing  physicians' practices. In:  Mass  Medical  Soc; 1993.  
51. Aarons  GA, Sklar  M, Mustanski  B, Benbow  N, Brown  CH. “Scaling -out” evidence -based  
interventions  to new  populations  or new  health  care  delivery systems.  Implementation 
Science.  2017;12(1):111.  
52. Garbutt JM, Yan Y, Highstein  G, Strunk  RC. A cluster -randomized  trial shows  telephone  peer 
coaching  for parents  reduces  children's  asthma  morbidity.  Journal  of Allergy  and Clinical 
Immunology.  2015;135(5):1163- 1170.  e1162.  
53. Tabak  RG, Chambers  DA, Hook  M, Brownson  RC. Dissemination  and Implementation  
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
46 
 Research  in Health: Translating  Science  to Practice  In: Oxford  University Press;  2018.  
54. Michie  S, van Stralen  MM, West  R. The behaviour  change  wheel:  a new  method  for 
characterising  and designing  behaviour  change  interventions.  Implement Sci.  2011;6:42.  
55. Finer  LB, Philbin  JM. Sexual  initiation,  contraceptive  use, and pregnancy  among  young  
adolescents.  
Pediatrics.  2013;131(5):886- 891.  
56. Copen  CE, Chandra  A, Martinez  G. Prevalence  and timing  of oral sex  with  opposite -sex 
partners  among  females  and males  aged  15-24 years:  United  States, 2007- 2010.  Natl  
Health  Stat Report.  2012(56):1- 14. 
57. Cavazos -Rehg  PA, Krauss  MJ, Spitznagel EL, et al. Age of sexual  debut among  US adolescents.  
Contraception.  2009;80(2):158- 162.  
58. Jena  AB, Goldman  DP, Seabury  SA. Incidence  of sexually  transmitted  infections  after human  
papillomavirus  vaccination  among  adolescent  females.  JAMA  internal  medicine.  
2015;175(4):617- 623.  
59. Bednarczyk  RA, Davis  R, Ault K, Orenstein  W, Omer SB.  Sexual  activity -related  outcomes  after 
human  papillomavirus  vaccination  of 11- to 12-year- olds.  Pediatrics.  2012;130(5):798- 805.  
60. Romanowski  B, Schwarz TF,  Ferguson  L, et al. Sustained  immunogenicity  of the HPV -16/18 
AS04-  adjuvanted  vaccine  administered  as a two-dose  schedule  in adolescent  girls: five -year  
clinical data  and modeling  predictions  from  a randomized  study.  Human  vaccines  & 
immunotherapeutics.  2016;12(1):20-  29. 
61. CDC. Human Papillomavirus (HPV) Resources for Health Professionals.  
https://www.cdc.gov/hpv/hcp/resources.html. Accessed March 9th, 2018.  
62. Scherr C,  Augusto  B, Ali K, Malo  T, Vadaparampil  S. Provide r-reported  acceptance  and 
use of the Centers  for Disease  Control and  Prevention  messages  and materials  to 
support  HPV  vaccine  recommendation  for adolescent males.  Vaccine.  
2016;34(35):4229- 4234.  
63. Margolis  PA, Lannon  CM, Stuart JM, Fried  BJ, Keyes -Elstein  L, Moore  DE, Jr.  Practice  
based  education  to improve  delivery systems for  prevention  in primary care: 
randomised  trial.  BMJ.  2004;328(7436):388.  
64. Pink  DH. Drive: The  Suprising  Truth  About What  Motivates  Us. 375 Hudson  Street,  New  
York, New  York  10024,  USA: Riverhead  Books, Penguin  Group  (USA) Inc.; 2009.  
65. Ruhe  MC, Carter C, Litaker D, Stange  KC. A systematic  approach  to practice  assessment and  
quality  improvement intervention  tailoring.  Quality  Management in Healthcare.  
2009;18(4):268- 277.  
66. Meropol SB,  Schiltz  NK, Sattar  A, et al. Practice -tailored  facilitation  to improve  pediatric  
preventive  care  delivery:  a randomized  trial.  Pediatrics.  2014;133(6):e1664- e1675.  
67. Huijg  JM, Gebhardt  WA,  Dusseldorp  E, et al. Measuring  determinants  of implementation  
behavior:  psychometric  properties  of a questionnaire  based  on the theoretical domains  
framework.  Implementation  Science.  2014;9(1):33.  
68. Malo  TL, Hall ME, Brewer  NT, Lathren  CR, Gilkey  MB. Why  is announcement training  more  
effective  than  conversation  training  for introducing  HPV  vaccination?  A theory -based  
investigation.  Implementation  Science.  2018;13(1):57.  
69. Coalition IA. Suggestions to improve your immunization services. 2006;  http://www.immunize.org/catg.d/p2045.pdf.  
70. Cohen  DJ, Crabtree  BF, Etz RS, et al. Fidelity  versus  flexibility:  translating  evidence- based  
research  into practice. American journal  of preventive  medicine.  2008;35(5):S381- S389.  
71. Shelley  DR, Ogedegbe  G, Anane  S, et al. Testing  the use of practice  facilitation  in a cluster 
randomized  stepped -wedge  design  trial to improve  adherence  to cardiovascular disease  
HPV Vaccine Use in Primary Care                       Version 1.10  
Protocol  6 February,2023  
 
 
47 
 prevention  guidelines:  HealthyHearts  NYC.  Implementation Science.  2016;11(1):88.  
72. Baskerville  NB, Liddy  C, Hogg  W. Systematic  review  and meta -analysis  of practice  
facilitation  within  primary  care  settings.  The Annals  of Family  Medicine.  2012;10(1):63- 74. 
73. Abry T, Hulleman  CS, Rimm -Kaufman  SE. Using  indices  of fidelity  to intervention  core  
components  to identify  program  active  ingredients.  American  Journal  of Evaluation.  
2015;36(3):320- 338.  
74. Chamberlain  P, Brown  CH, Saldana  L. Observational measure  of implementation  progress  
in community  based  settings: the stages  of implementation  completion  (SIC).  
Implementation  Science.  2011;6(1):116.  
75. Weiner  BJ, Lewis  CC, Stanick  C, et al. Psychometric  assessment of three  newly  
developed  implementation  outcome  measures.  Implementation  Science.  
2017;12(1):108.  
76. Moss  JL, Reiter PL, Rimer  BK, Brewer  NT. Collaborative  patient -provider communication  and 
uptake  of adolescent  vaccines.  Social Science  & Medicine.  2016;159:100- 107.  
77. Ritzwoller  DP, Sukhanova  A, Gaglio  B, Glasgow  RE. Costing  Behavioral  Interventions: A 
Practical  Guide  to Enhance  Translation.  Annals  of Behavioral Medicine.  2009;37(2):218-
227.  
78. Little  RJ, Rubin  DB. Statistical analysis  with  missing  data.  Vol 333: John  Wiley  & Sons; 2002 
79. Taylor,  A., MacKinnon,  D. and  Tein,  J. (2008).  Tests  of the three -path  mediated  effect.  
Organizational  Research  Methods , 11, 241- 269.  
 
 